^
    BIOMARKER:

    PD-L1 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Contact us to learn more about our Premium Content:
    News alerts, weekly reports and conference planners
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    PD-L1 expression
    Melanoma
    pembrolizumab
    Sensitive
    :
    B
    ESMO 2022 - 3 weeks - (New B)
    PD-L1 expression
    Non Small Cell Lung Cancer
    Immunotherapy
    Sensitive
    :
    C3
    ESMO 2022 - 3 weeks - (New C3)
    PD-L1 expression
    Non Small Cell Lung Cancer
    PD1 inhibitor
    Sensitive
    :
    C3
    Cancers (Basel) - 3 weeks - (New C3)
    PD-L1 expression
    Non Small Cell Lung Cancer
    PD-L1 inhibitor
    Sensitive
    :
    C3
    Cancers (Basel) - 3 weeks - (New C3)
    PD-L1 expression
    Non Small Cell Lung Cancer
    atezolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Triple Negative Breast Cancer
    atezolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Non Small Cell Lung Cancer
    pembrolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Non Small Cell Lung Cancer
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive
    :
    A1
    PD-L1 expression
    Urothelial Cancer
    atezolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Non Small Cell Lung Cancer
    durvalumab
    Sensitive
    :
    A1
    PD-L1 expression
    Squamous Cell Carcinoma of Head and Neck
    pembrolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Renal Cell Carcinoma
    avelumab + axitinib
    Sensitive
    :
    A1
    PD-L1 expression
    Triple Negative Breast Cancer
    pembrolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Cervical Cancer
    pembrolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Urothelial Cancer
    pembrolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Esophageal Cancer
    pembrolizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Urothelial Cancer
    nivolumab
    Sensitive
    :
    A1
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    PD-L1 expression
    Cervical Cancer
    pembrolizumab + bevacizumab
    Sensitive
    :
    A1
    PD-L1 expression
    Non Small Cell Lung Cancer
    cemiplimab
    Sensitive
    :
    A1
    PD-L1 expression
    Oral Cancer
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Oropharyngeal Cancer
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Squamous Cell Carcinoma of Head and Neck
    ADX-2191
    Sensitive
    :
    A2
    PD-L1 expression
    Squamous Cell Carcinoma of Head and Neck
    cetuximab
    Sensitive
    :
    A2
    PD-L1 expression
    Squamous Cell Carcinoma of Head and Neck
    5-fluorouracil
    Sensitive
    :
    A2
    PD-L1 expression
    Gastric Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Bladder Cancer
    atezolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Lung Non-Squamous Non-Small Cell Cancer
    atezolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Bladder Cancer
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Esophageal Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Renal Cell Carcinoma
    nivolumab
    Sensitive
    :
    A2
    PD-L1 expression
    Head and Neck Cancer
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Lung Non-Small Cell Squamous Cancer
    nivolumab + ipilimumab
    Sensitive
    :
    A2
    PD-L1 expression
    Lung Non-Squamous Non-Small Cell Cancer
    nivolumab + ipilimumab
    Sensitive
    :
    A2